VANGUARD GROUP INC 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:09 pm Sale | 2023-12-29 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 12,042,873 6.310% | -13,314 (-0.11%) | Filing |
| 2023-07-10 10:41 am Sale | 2023-06-30 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 12,056,187 6.370% | -11,009,588 (-47.73%) | Filing |
| 2023-02-09 11:27 am Purchase | 2022-12-30 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 23,065,775 12.270% | 4,553,864 (+24.60%) | Filing |
| 2022-01-10 11:49 am Purchase | 2021-12-31 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 18,511,911 10.030% | 2,239,326 (+13.76%) | Filing |
| 2021-02-10 11:28 am Purchase | 2020-12-31 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 16,272,585 9.070% | 114,974 (+0.71%) | Filing |
| 2020-02-12 08:02 am Sale | 2019-12-31 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 16,157,611 9.180% | -2,146,920 (-11.73%) | Filing |